搜索历史清除全部记录
最多显示8条历史搜索记录噢~
全部
  • 全部
  • 产品管理
  • 新闻资讯
  • 介绍内容
  • 企业网点
  • 常见问题
  • 企业视频
  • 企业图册

+
  • V75868.jpg

PRMT5-抑制剂27

PRMT5-抑制剂27,PRMT5-IN-27,是 PRMT5 的抑制剂(阻断剂/拮抗剂)。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。


关键词

PRMT5-抑制剂27


所属分类


目录号

V75868

  • 产品描述
  • 产品组分
  • 文件资源
  • 营销中心
  • 注意事项
  • FAQ
  • 文献追踪
  • AMG-193 (PRMT5-IN-27; compound 481 是 PRMT5 的抑制剂(阻断剂/拮抗剂)。 PRMT5-IN-27 抑制 HCT116 细胞生长/增殖,IC 50 为 0.107 μM。

    靶点
    PRMT5
    体外研究 (In Vitro)
    AMG 193是第二代蛋白质精氨酸甲基转移酶5(PRMT5)抑制剂,靶向甲硫腺苷磷酸化酶(MTAP)无效肿瘤中PRMT5的MTA结合状态。PRMT5负责癌症中失调的细胞必需蛋白的甲基化和基因沉默,并在含有MTAP缺失的肿瘤中受到部分抑制,约15%的实体瘤发生这种情况[2]。
    体内研究 (In Vivo)
    第一代PRMT5抑制剂是不可容忍的,因为PRMT5的不加区分的抑制导致剂量限制性骨髓抑制。在临床前研究中,AMG 193通过进一步抑制PRMT5功能,同时保留正常功能,从而改善第一代分子,在MTAP无效模型中证明了选择性抗肿瘤活性。我们报告了正在进行的首次人体(FIH)研究中剂量增加的初步临床结果[2]。
    动物实验
    Methods: AMG193 was orally administered in continuous 28-day cycles to patients (pts) with advanced MTAP-null solid tumors. Dose escalation proceeded via a BLRM method. The primary objectives include safety, tolerability, and identification of the maximum tolerated dose (MTD). Secondary objectives include preliminary antitumor activity by investigator-assessed RECIST, pharmacokinetics (PK) and pharmacodynamic (PD) effects.[2]
    Results: As of August 8, 2023, 47 pts with MTAP-null cancer (PDAC n = 10; NSCLC n = 6; CCA = 5; MESO n = 3; others n = 23) were enrolled in seven escalating cohorts. Five pts had DLTs, and exploration continues per protocol to identify the MTD. The most common TRAEs were nausea (45%), fatigue (26%), decreased appetite (17%), and vomiting (17%). Preliminary PK analyses showed dose-proportional systemic exposure with a half-life of 7–11 hrs. Among 31 pts who had at least one postbaseline scan, there were 5 with confirmed PRs [PDAC (–100%), ovarian Sertoli-Leydig (–59%), RCC (–58%), esophageal (–46%), and gallbladder cancer (–63%), 1 each], 14 with stable disease (including 9 with some degree of tumor shrinkage), and 12 with disease progression. All PRs were ongoing at the data cutoff with treatment durations of 140–275 days. PD effects demonstrated dose-dependent reduction in serum total SDMA levels and complete PRMT5 inhibition was confirmed in five pts with on-treatment biopsies spanning multiple dose levels. Exploratory analysis of changes in variant allele frequency by ctDNA demonstrated rapid treatment effects that was predictive and correlated with response.[2]
    Conclusion: AMG 193 is an MTA-cooperative PRMT5 inhibitor designed to induce synthetic lethality in MTAP-null solid tumors while sparing hematologic toxicity. The initial results of the FIH study demonstrate proof-of-concept with encouraging signs of preliminary clinical activity without evidence of myelosuppression. Dose escalation continues to proceed to establish the MTD. AMG 193 has demonstrated promise as a potential new therapeutic for pts with tumors that have MTAP loss[2].
    参考文献
    [1]. AMG 193 Effective in Multiple Tumor Types. Cancer Discov. 2023 Dec 12;13(12):2492. doi: 10.1158/2159-8290.CD-NB2023-0079.
    [2].Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors. Mol Cancer Ther (2023) 22 (12_Supplement): PR006. https://doi.org/10.1158/1535-7163.TARG-23-PR006.
    [3]. Shon Booker, et al. Prmts inhibitors. WO2022132914A1. 2022-06-23.
    其他信息
    The second-generation PRMT5 inhibitor AMG 193 (Amgen) yielded partial responses in patients with a variety of tumor types while avoiding the toxicity associated with such first-generation agents. Reported at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 11–15 in Boston, MA, the findings point to a possible treatment avenue for the 10% to 15% of patients who have MTAP-deleted solid tumors.
    “PRMT5 is responsible for methylation and gene silencing of cell-essential proteins dysregulated in cancer,” explained Jordi Rodón, MD, PhD, of The University of Texas MD Anderson Cancer Center in Houston, who presented the findings. But broadly targeting PRMT5, as researchers had learned, caused serious myelosuppression and other intolerable effects, necessitating a different plan of attack.
    On the biology front, researchers knew that tumors with MTAP loss accumulate the metabolite MTA. “Interestingly,” Rodón continued, “MTA is a natural inhibitor of PRMT5, so tumors having MTAP loss accumulate MTA and have a partial inhibition of PRMT5. With chemical mastery, you can develop drugs that bind to PRMT5 only in the presence of MTA,” killing tumor cells while sparing healthy ones.
    View More

    That's the thinking behind the new class of drugs called MTA-cooperative PRMT5 inhibitors, of which AMG 193 is one. Another is Mirati's MRTX1719. Boston-based Tango Therapeutics, which has two MTA-cooperative PRMT5 inhibitors in early-stage trials, Kraków, Poland's Ryvu Therapeutics, and Shanghai, China's Abbisko Therapeutics presented preclinical research on their respective agents at the Molecular Targets conference as well.
    Having demonstrated that AMG 193 exploits this tumor-specific vulnerability in preclinical studies, Rodón and his team enrolled 48 patients with advanced solid tumors into a first-in-human phase I trial of the agent. Ten patients had pancreatic adenocarcinoma, seven had non–small cell lung cancer, five had cholangiocarcinoma, and three had mesothelioma; the remaining 23 patients had other types of cancer. All the patients had already tried at least one other therapy, with one third having tried four or more.
    Patients received one of seven doses of AMG 193, ranging from 40 mg to 1,600 mg a day, with those taking the higher doses seeing greater tumor shrinkage. Overall, of the 31 patients who received at least one scan after starting treatment, five—one each with esophageal, pancreatic, renal cell, gallbladder, and ovarian Sertoli-Leydig cell cancer—experienced a partial response. Fourteen others had stable disease, nine of whom experienced some tumor shrinkage.
    Rodón reported that 39 patients (81.3%) experienced treatment-related adverse events (TRAE), most commonly nausea, fatigue, loss of appetite, and vomiting, and most often at the higher doses. Three patients discontinued treatment due to TRAEs. Rodón noted that AMG 193 didn't cause significant neutropenia or thrombocytopenia, which had proven problematic with first-generation PRMT5 inhibitors.
    “The new class of MTA-cooperative PRMT5 inhibitors does appear promising,” said Pasi Jänne, MD, PhD, of Dana-Farber Cancer Institute in Boston, who has been involved in research on MRTX1719 (Cancer Discov 2023;11:2412–31).
    “MTAP deletions are found across cancers, which is an advantage for this class of agents, as there are no approved targeted therapies for many cancers with MTAP deletions—for example mesotheliomas or pancreas cancers,” Jänne said. But because MTAP loss is found in so many malignancies, he cautioned that more patients need to be enrolled in this trial and in others “to get a true sense of activity.”
    David Kwiatkowski, MD, PhD, of Brigham and Women's Hospital in Boston and Dana-Farber, who is also involved in the Mirati study, said he is “quite enthusiastic and optimistic” about the future of MTA-cooperative PRMT5 inhibitors. He has a patient with mesothelioma enrolled in a study of MRTX1719 who's had a “fabulous response. He's been on it for a year, tolerating it, and feeling good.”
    In total, six of 18 evaluable patients in the phase I/II MRTX1719 study had confirmed responses to the drug.
    Thanks to the preclinical and early clinical studies, the mechanism of action of MTA-cooperative PRMT5 inhibitors “has been validated,” Kwiatkowski continued. “This isn't just one drug, or one company. It's multiple drugs, multiple companies. It's exciting.” –Suzanne Rose.
    Referencess: https://aacrjournals.org/cancerdiscovery/article/13/12/2492/731594/AMG-193-Effective-in-Multiple-Tumor-TypesAMG-193

    *注: 文献方法仅供参考, IVDSHOW并未独立验证这些方法的准确性。
    分子式

    C22H19F3N4O3

    分子量

    444.406475305557

    精确质量

    444.14

    CAS号

    2790567-82-5

    PubChem CID

    164536956

    外观&性状

    Typically exists as solid at room temperature

    LogP

    1.8

    tPSA

    90.6Ų

    氢键供体(HBD)数目

    1

    氢键受体(HBA)数目

    9

    可旋转键数目(RBC)

    2

    重原子数目

    32

    分子复杂度/Complexity

    688

    定义原子立体中心数目

    1

    SMILES

    C1COC[C@@H](N1C(=O)C2=NC=C3C(=C2)C4=C(COC4)C(=N3)N)C5=CC=C(C=C5)C(F)(F)F

    InChi Key

    BFEBTMFPRJPBTK-LJQANCHMSA-N

    InChi Code

    InChI=1S/C22H19F3N4O3/c23-22(24,25)13-3-1-12(2-4-13)19-11-31-6-5-29(19)21(30)17-7-14-15-9-32-10-16(15)20(26)28-18(14)8-27-17/h1-4,7-8,19H,5-6,9-11H2,(H2,26,28)/t19-/m1/s1

    化学名

    (4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]methanone

    别名

    AMG193; AMG-193

    HS Tariff Code

    2934.99.9001

    存储方式

    Powder      -20°C    3 years

                         4°C     2 years

    In solvent   -80°C    6 months

                      -20°C    1 month

    运输条件

    Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

  • 产品组分

    内容 型号 规格

    储存温度

    PRMT5-抑制剂27 V75868-01 500mg -20°C
    PRMT5-抑制剂27 V75868-02 1g -20°C
    PRMT5-抑制剂27 V75868-03 5g -20°C

    操作手册

    1 1

    常温

  • 文件资源

    文件下载 文件内容 资源说明
    V75868-PRMT5-抑制剂27 操作手册
    V75868-PRMT5-抑制剂27相关单页 宣传单页

     

  • 营销中心1

  • 注意事项

    保存建议 厂家推荐蓝冰运输。当您收到产品后,按照说明书建议保存于-20°C。

     

  • FAQ

在线留言

如果您对我们的产品感兴趣,请留下您的信息,我们将尽快与您联系,谢谢!

图片名称

艾维缔官网

图片名称
图片名称

艾德官网

图片名称
图片名称

B站IVDSHOW

图片名称
图片名称

抖音军哥聊表观

图片名称
图片名称

视频号艾维缔

图片名称
图片名称

小红书艾维缔

图片名称
图片名称

快手表观盒子

图片名称
图片名称

表观遗传学

图片名称

联系我们

Tel:+86-0313-5935521|18911529660

ADD:张家口市怀来县东花园镇哈工大研究院T8幢7层

邮箱:1951545998@qq.com

留言咨询

如果您对我们的产品和服务感兴趣,请留下您的信息。

立即咨询 →

IVDSHOW

订阅我们,以便及时了解产品更新和特惠活动

%{tishi_zhanwei}%
售后反馈 →

免责申明:本网站销售的所有产品均不得用于人类或动物之临床诊断或治疗,仅可用于工业或者科研等非医疗目的。(获得国家相关部门批准的产品除外) 

版权所有:艾维缔科技怀来有限公司 

营业执照